Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple ...

Nkarta’s allogeneic, CD19-directed chimeric antigen receptor (CAR) NK-cell therapy in patients with systemic lupus erythematosus (SLE). The IST broadens the clinical eval SOUTH SAN FRANCISCO ...

Nkarta stock surged Monday — partially reversing ... In this case, those are CD19 cells. After three months, the five patients no longer had any CD19 cells in their blood. Also promisingly ...

Nkarta has singled out a group of five patients ... which like approved CAR-Ts such as Gilead’s Yescarta and Novartis' Kymriah targets CD19. Three of six patients (50%) with relapsed/refractory ...

Nkarta (NASDAQ:NKTX – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.39) per ...

Sequoia Financial Advisors LLC purchased a new position in shares of Nkarta, Inc. (NASDAQ:NKTX – Free Report) during the fourth quarter, according to the company in its most recent filing with the ...

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced ...

The study "adds further support to CD19 T-cell engagers being able to deliver ... (IPSC), Gilead Sciences (GILD), Morphosys (MOR), Nkarta (NKTX), and Novartis (NVS).

Nkarta’s allogeneic, CD19-directed chimeric antigen receptor (CAR) NK-cell therapy in patients with systemic lupus erythematosus (SLE). The IST broadens the clinical eval SOUTH SAN FRANCISCO, Calif., ...